Find policies, billing codes, payers, states, and providers
Diagnosis of Idiopathic Environmental Intolerance
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Oscar Health's coverage stance for diagnostic testing and evaluation related to idiopathic environmental intolerance (IEI)/multiple chemical sensitivity, including limits on laboratory and proprietary tests; applies to providers submitting claims for members covered by Oscar Health.
No material clinical or coverage changes in this revision.
Coverage Criteria for IEI / Multiple Chemical Sensitivity
Tests and specimen analyses that do not meet criteria for IEI diagnosis
Not covered — tests and situations that do not meet criteria
Categorical denial applies regardless of setting.
List taken directly from policy exclusions (III. Indications and/or Limitations of Coverage).
Covered when clinically indicated with appropriate pretest evaluation
Coverage considerations for breath testing and related evaluations when clinically indicated:
Reflects guideline statements that breath testing is useful in symptomatic patients without alternative diagnoses.
Reflects North American Expert Consensus and ACG recommendations (conditional/low–moderate evidence) and Rangan review findings on substrate differences.
Draws on Rangan review and North American Expert Consensus guidance about transit time limitations and predisposing conditions.
Proprietary multi-analyte panels and broad micronutrient or toxicant panels are considered unnecessary for diagnosing idiopathic environmental intolerance (IEI) and do not meet coverage criteria when used for that purpose. Examples called out in the policy include Genova Diagnostics panels such as the Organix Comprehensive Profile, NutrEval, Food Sensitivity+, the GI Effects Profile, Ion Profile, Comprehensive Digestive Stool Analysis (CDSA) 2.0 and SIBO Profile; SpectraCell Laboratory tests including the Micronutrient Test and SPECTROX™; Life Extension nutrient panels; Vibrant Wellness nutrient panels; and Metabolomix+. These panels test many analytes (for example, up to 118 markers on some panels) but the policy states their routine use to diagnose IEI is not supported because IEI lacks reliable, testable characteristics.
The policy explains that while some individual component tests within these panels (for example, stool culture, elastase, or tests for specific micronutrient deficiencies) may have legitimate indications in other clinical contexts, ordering these broad proprietary panels specifically to ‘‘confirm’’ or diagnose IEI is not appropriate and will not meet criteria.
Major medical societies have expressed skepticism about IEI (formerly multiple chemical sensitivity) and advise against use of nonvalidated immune-based or otherwise unsupported laboratory tests to establish the diagnosis. The American Medical Association historically has stated IEI should not be recognized as a syndrome until accurate, reproducible, well-controlled studies exist, and the American College of Physicians and the American Academy of Allergy, Asthma & Immunology have expressed similar reservations.
Specifically, the American Academy of Allergy, Asthma & Immunology (AAAAI) has noted that use of many nonvalidated immune-based tests to support an immunologic basis for IEI is expensive, not useful or valid, and should be discouraged — a position that supports excluding such tests when they are ordered to diagnose IEI.
A targeted search identified no FDA-approved or -cleared diagnostic test for idiopathic environmental intolerance. The policy notes that many laboratories perform in-house assays that are laboratory-developed tests (LDTs); these LDTs are regulated under CLIA as high-complexity tests but are not approved or cleared by the U.S. Food and Drug Administration.
Laboratory tests and proprietary panels intended to confirm IEI or to screen asymptomatic individuals without abnormal findings do not meet criteria. The policy lists multiple specimen-based screens (volatile solvents, organic acids, organophosphates), profiling of phthalates/parabens and chlorinated pesticides, vitamin/mineral/nutritional analyses, metals testing in various matrices, and breath hydrogen/methane testing among those that do not meet criteria when used to diagnose or screen for IEI.
The policy emphasizes that because IEI lacks a reliable laboratory signature, ordering broad, non–evidence-based panels or using tests to ‘‘prove’’ IEI in asymptomatic or general encounters is not medically justified and may be denied.
The policy identifies tests that lack standardization or validation as not supported for diagnosing IEI. This includes many carbohydrate breath tests and other breath testing approaches where preparation, performance, interpretation, and indications vary across centers, producing considerable heterogeneity and limited validation.
Reviews cited in the policy note that for several carbohydrate breath tests (for example, fructose or sorbitol), no gold standard exists and validation studies are insufficient; even when breath tests are inexpensive and simple, the lack of standardization limits their accuracy and clinical utility for diagnosing IEI.
Procedure and Billing Codes
| 82108 | Aluminum. |
| 82127 | Amino acids; single, qualitative, each specimen. |
| 82136 | Amino acids, 2 to 5 amino acids, quantitative, each specimen. |
| 82139 | Amino acids, 6 or more amino acids, quantitative, each specimen. |
| 82300 | Cadmium. |
| 82379 | Carnitine (total and free), quantitative, each specimen. |
| 82380 | Carotene. |
| 82441 | Chlorinated hydrocarbons, screen. |
| 82495 | Chromium. |
| 82507 | Citrate. |
| 82108 | Aluminum. |
| 82127 | Amino acids; single, qualitative, each specimen. |
| 82136 | Amino acids, 2 to 5 amino acids, quantitative, each specimen. |
| 82139 | Amino acids, 6 or more amino acids, quantitative, each specimen. |
| 82300 | Cadmium. |
| 82379 | Carnitine (total and free), quantitative, each specimen. |
| 82380 | Carotene. |
| 82441 | Chlorinated hydrocarbons, screen. |
| 82495 | Chromium. |
| 82507 | Citrate. |
| Breath hydrogen/methane test (unnumbered in list) | Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit). |
Provider Actions, Documentation, and Authorization
Coverage restriction — IEI diagnostic tests are not covered
In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) do not meet criteria and are subject to denial when billed as diagnostic confirmation; a broad set of specimen‑based panels (volatile solvents, organic acids, phthalates/parabens, chlorinated pesticides including DDE/DDT, vitamin/mineral/nutritional analyses, metals testing, and breath hydrogen/methane) are explicitly listed as not meeting criteria.
- Categorical exclusion applies regardless of setting.
- Breath hydrogen and/or breath methane testing is listed as not meeting criteria.
Document specific procedure codes when ordering tests
The policy lists numerous CPT/HCPCS codes for laboratory assays and related procedures that may be ordered in IEI evaluations; providers should be aware these procedure codes are enumerated in the policy and include heavy metals, organic acids, amino acids, and other specialty assays.
Prior authorization may apply for listed specialty tests
Prior authorization may be required for many specialized laboratory and diagnostic tests listed for IEI evaluation; verify payer PA requirements before ordering to avoid claim denials.
- Policy note: "Prior authorization may be required per payer policy for many specialized laboratory and diagnostic tests listed by CPT/HCPCS when used for diagnosing idiopathic environmental intolerance; verify PA requirements before ordering."
Clinical evaluation and basic testing must precede specialized testing
Perform a clinical‑first evaluation: obtain a focused history (including occupational/environmental exposures), physical exam, and basic laboratory testing (CBC, serum electrolytes and glucose, urinalysis) and use screening tools (eg, EESI, PHQ‑9) as clinically appropriate before ordering specialized or proprietary panels.
- Use targeted testing guided by reported symptoms; psychiatric screening is recommended since psychiatric comorbidity is common.
- Avoid ordering specialized IEI panels without completing basic clinical evaluation documented in the record.
Link breath testing to antibiotic‑directed therapeutic intent
Breath hydrogen/methane testing is described as useful when intended to identify antibiotic‑responsive microbial colonization (eg, SIBO) or to evaluate methane in patients with constipation; document clinical indication and how results would change management (eg, guide antibiotic therapy).
- Policy: breath testing may be used to assess antibiotic‑responsive microbial colonization and to evaluate methane with constipation.
- Document predisposing conditions (prior GI surgery, recent antibiotics, transit issues) that affect interpretation.
Step therapy guidance — none provided
No step therapy requirements are specified in this policy section.
- The policy explicitly states that no step therapy guidance is provided in this section.
Required documentation — history, exam, basic labs, screening tools
When requesting coverage or authorization, submit complete clinical documentation: history of compatible symptoms, physical exam findings, occupational/environmental exposure history, pertinent basic labs (CBC, electrolytes, glucose, urinalysis), and use of screening tools (EESI, PHQ‑9) where relevant.
- Include documentation of prior evaluation steps and why basic testing did not explain symptoms.
- Occupational/environmental history should be recorded when relevant.
Clinical justification and diagnostic workup required
Provide clinical justification and supporting diagnostic workup when ordering specialized tests: document compatible symptoms (eg, bloating, abdominal pain, gas, diarrhea, constipation), absence of alternative diagnoses on endoscopy or imaging, and consideration of predisposing conditions (eg, prior surgery, motility disorders) that make the test appropriate.
- Policy notes breath testing is useful only in symptomatic patients without another diagnosis on endoscopy or imaging.
- Consider and document factors that influence test interpretation (orocecal transit variability, recent antibiotics).
Document exact procedure codes and clinical rationale
When ordering tests for IEI, document the specific CPT/HCPCS procedure codes used from the policy code list and include the clinical rationale for each test in the medical record or PA submission.
- The policy provides a full list of applicable procedure codes; include the exact code(s) on orders and authorization requests.
- Failure to document specific procedure codes and rationale may lead to administrative denial or recoupment.
High denial risk — tests intended to confirm IEI
Ordering laboratory tests intended to confirm IEI will not meet coverage criteria and is a categorical basis for denial; do not order tests solely to 'confirm' IEI without meeting policy prerequisites and documentation requirements.
- Policy statement: "In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance DO NOT MEET CRITERIA."
Societal skepticism of IEI testing may prompt denials
Major medical societies (AMA, ACP, AAAAI) have expressed skepticism about IEI/MCS and discourage nonvalidated immune‑based or proprietary tests; this societal position may be cited in payer denials of such testing.
- Policy cites AMA 1992 statement and similar positions from other societies as rationale for discouraging nonvalidated tests.
Regulatory status (no FDA‑cleared tests) increases scrutiny
Because no FDA‑cleared or approved test for IEI was identified and many tests are laboratory‑developed tests (LDTs), these tests may receive increased payer scrutiny and potential denials absent strong clinical justification and validation.
- Policy: "No specific U.S. Food and Drug Administration (FDA) approval or clearance of a test for idiopathic environmental intolerance was found."
- Document why an LDT is necessary and provide validation/clinical rationale when possible.
LDT regulatory context — CLIA‑regulated, not FDA‑cleared
Tests performed as laboratory‑developed tests (LDTs) are regulated under CLIA as high‑complexity tests and are not FDA‑approved or cleared; payers may subject LDTs to additional coverage review and potential denial if validation or clinical utility is not demonstrated.
- Policy: LDTs "are regulated by the Centers for Medicare and Medicaid (CMS) as high‑complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U.S. Food and Drug Administration."
- If ordering an LDT, include documentation of the test's CLIA status and supporting validation/utility evidence where available.
Background and Scope
Idiopathic environmental intolerance (IEI), previously referred to as multiple chemical sensitivity (MCS), is described as a subjective condition characterized by recurrent, nonspecific symptoms that patients attribute to low-level exposures to chemical, biological, or physical agents without consistent objective diagnostic findings. Symptoms reported in the policy are heterogeneous and can include manifestations such as anxiety, shortness of breath, chest pain, gastrointestinal complaints, and other nonspecific somatic symptoms.
The policy notes psychiatric comorbidity is common among affected individuals, and that there is no reliable laboratory signature for IEI. Because clinical presentations are variable and objective testing is generally lacking, the document advises a clinical-first evaluation (history, physical exam, targeted basic labs and selected objective testing) and cautions against reliance on unvalidated or broad laboratory panels to establish the diagnosis.
Key Definitions and Instruments
Policy Revision History
An international Consensus Document (1999) establishing recognition criteria for Multiple Chemical Sensitivity (MCS) is cited as the most widely used criteria for recognition of MCS/IEI.
Policy last reviewed by governance (document shows 'Last review 2026-06-16').
Policy effective date recorded as 2026-10-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.